What is RenalGuard Solutions?
RenalGuard Solutions, operating under the umbrella of CardioRenal Systems, Inc., is a specialized medical technology developer focused on the prevention of AKI during complex cardiac procedures. The company's flagship innovation, the RenalPro system, has earned FDA breakthrough device designation for its autonomous fluid therapy management capabilities. By integrating directly into existing hospital workflows, the platform provides a sophisticated, data-driven approach to patient care. Clinical evidence supporting the technology is robust, with studies indicating a 52% reduction in AKI rates, positioning the company as a leader in the niche but high-growth sector of renal protection and hemodynamic optimization.
How much funding has RenalGuard Solutions raised?
RenalGuard Solutions has raised a total of $7M across 1 funding round:
Series A
$7M
Series A (2018): $7M, investors not publicly disclosed
Key Investors in RenalGuard Solutions
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for RenalGuard Solutions?
With the recent influx of capital, RenalGuard Solutions is poised to scale its commercial operations and expand its footprint within major healthcare institutions. The strategic roadmap likely involves deepening market penetration for the RenalPro system and potentially initiating further clinical trials to broaden the device's application across diverse surgical specialties. As the company transitions from a development-focused entity to a commercial-stage enterprise, the focus will shift toward optimizing supply chain logistics and strengthening clinical partnerships. This growth trajectory suggests a long-term commitment to establishing a new standard of care in fluid management, ultimately aiming to reduce the significant economic and health burdens associated with hospital-acquired kidney injuries.
See full RenalGuard Solutions company page
